A multicenter, randomized, double-blind, placebo-controlled study on the efficacy and safety of abatacept combined with conventional drugs in the treatment of systemic sclerosis (ChiCTR) - Oct 16, 2026 - P4 | N=78 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
New P4 trial • Immunology • Scleroderma • Systemic Sclerosis
|